The 2026 Zhangjiang Pharma Conference and the opening forum of Shanghai International Biomedical Industry Week were held, featuring a fireside chat between Nobel Chemistry laureate Michael Levitt and Insilico Medicine CEO Ren Feng. Levitt said AI-driven drug development has surpassed his expectations, while Ren's team has advanced the world's first innovative drug with AI-identified targets and AI-designed molecular structures into Phase III clinical trials.